what’s hot in diagnostic microbiology? · arch pathol lab med 2012 (early online release) •...
TRANSCRIPT
Slide 1
What’s Hot in DIAGNOSTIC MICROBIOLOGY?
Susan M. Poutanen, MD, MPH, FRCPCMicrobiologist/ID Consultant, UHN/MSH
Assistant Professor, U. of Toronto
AMMI Canada – CACMID 2013
Slide 2
Objectives1. To highlight a selection of the most
important and interesting literature in diagnostic microbiology from the last year
2. To review how these developments may influence diagnostic microbiology practice
Slide 3
Disclosures• Advisory Board/Consultant
– Optimer– Sunovion
• Speakers Bureau– Merck– Hoffman La Roche
• Research Support– Biomérieux– Bio-Rad– Copan– Pathogenica
Slide 4
The Most Important and Interesting Literature in Diagnostic Microbiology
in the Last Year
MALDI-TOF
Next Generation Sequencing
Random Access Automated PCR
Automation
Fecal Transplants? – be prepared to be asked!
Slide 5
MALDI-TOF
• Matrix-assisted laser deionization-time of flight
Slide 6
Detection
Separation
Acceleration
Ionization
Desorption MALDI-TOF
Slide 7FEMS Microbiol Rev 2012;36:380-407
• Easy, rapid, high throughput, low cost, efficient identification tool of bacteria and yeast with potential applications to filamentous fungi, epidemiology, and resistance determinant identification
Slide 8FEMS Microbiol Rev 2012;36:380-407
Slide 9
study reference
organism/ # tested
% identified to genus/species
% misidentified/no ID
FEMS Microbiol Rev 2012;36:380-407
Slide 10
Slide 11Arch Pathol Lab Med 2012 (early online release)
• Implemented MALDI-TOF, rapid antimicrobial susceptibility, and near-real-time antimicrobial stewardship 24/7 in patients with positive blood cultures with Gram-negative organisms for a 3 m period and compared to a 3 m pre-intervention period
Slide 12Arch Pathol Lab Med 2012 (early online release)
• Results:– Significant ↓ TAT to ID and susceptibility testing– Significant ↓ mean hospital length of stay– Significant ↓ costs
Slide 13Arch Pathol Lab Med 2012 (early online release)
Results
Slide 14Arch Pathol Lab Med 2012 (early online release)
Results
Slide 15Clin Chem Lab Med 2013;51(2):257-270
• “Mass spectrometry is the future of microbiology…accurate identification …timely decision-making … optimal antibiotics, decrease multi-drug resistance ... reduce length and costs of hospitalization”
Slide 16
Next Generation Sequencing
• also referred to as deep sequencing
Slide 17
Slide 18
NEJM 2012;366:2267-75Lancet Infect Dis 2013;13:130-36PLOS One 2013;8(1):e54898
Slide 19BMC Inf Dis 2013, 13:110PLOS Medicine February 12, 2013
Slide 20Lancet 2013, published online March 29 2013
Slide 21Sci Trans Med 2012;4:148ra116PNAS 2012;109(8):3065-70
Slide 22
Whole Genomic Sequencing
• Challenge is translation from the research laboratory to the clinical laboratory given associated costs and technical and bioinformatics expertise
Slide 23www.pathogenica.com; Poster ASCP 2012
• Multiplexed deep sequencing assay that will:– Rapidly identify multiple pathogens (<12 hours)– Document epidemiologic relationship
Slide 24
Slide 25
Slide 26
Random Access Automated PCR
• Sensitive• Low risk of
contamination• Fast turn-around-
time (~45-70 min)• Low hands-on-time
Slide 27Journal of Infection 2013;64:580-8.
• A meta-analysis assessing the ability of the Xpert MTB/RIF (Cepheid) assay to diagnosis tuberculosis and RIF-resistance
Slide 28
• 18 studies (10,224 suspected specimens) • To detect pulmonary TB:
– Pooled Sn 90.4% (95%CI 89.2%-91.4%) – Pooled Sp 98.4% (95%CI 98.0%-98.7%)
• To detect extrapulmonary TB:– Pooled Sn 80.4%– Pooled Sp 86.1%
Journal of Infection 2013;64:580-8.
Results
Slide 29
Results (cont’d)• Detection of RIF-resistance
– Sn 94.1%– Sp 97.0%
• Subgroup analysis– Performance better in smear-positive specimens– Sn higher in pulmonary TB in adults than children
(90.8% versus 74.3%)• Conclusions: TB and RIF-resistance can be
rapidly and effectively diagnosed with XpertMTB/RIF assay.
Journal of Infection 2013;64:580-8.
Slide 30Cochrane Database of Systematic Review 2013, Issue 1.
• A meta-analysis assessing the ability of the Xpert MTB/RIF (Cepheid) assay to diagnosis tuberculosis and RIF-resistance
• 18 studies
Slide 31
Results
• Detect TB – Pooled Sn 88%
• smear pos 98%, smear neg 68%• HIV pos 80%, HIV neg 89%
– Pooled Sp 98%• Detect rifampin resistance
– Pooled Sn 94%– Pooled Sp 98%
Cochrane Database of Systematic Review 2013, Issue 1.
Slide 32
• Xpert used as an initial diagnostic test for TB detection and rifampin resistance detection in patients suspected of having TB, MDR-TB, or HIV-associated TB is sensitive and specific
• Xpert may also be valuable as an add-on test following microscopy for patients who have previously been found to be smear-negative
Conclusions
Cochrane Database of Systematic Review 2013, Issue 1.
Slide 33http://www.reuters.com/article/2010/12/08/us-tuberculosis-test-idUSTRE6B71RF20101208
Slide 34Future Microbiol. 2011;6(9):1067-82
• Described as potential “game changer” for TB control• Strong recommendation to use it as the initial
diagnostic test for ?MDR-TB and HIV-ass TB• Otherwise, given resource implications, recommend
to use it as a follow-up to microscopy
Slide 35J Virol Methods 2012;186:137-150
• Archived frozen NP swabs tested by RT-PCR • Sn (%) to detect influenza A/B
– Xpert 97.3/100, DFA 95.9/100– BinaxNOW 62.2/54.5, BD Directigen 71.6/48.5
• Sp 100% except DFA for influenza A 99.2%
Slide 36JCM 2012;50(5):1704-10
• Tested archived and prospective NP swabs or nasal aspirates comparing to culture and PCR as reference
• Sn to detect influenza A (90-100%), A 2009 H1N1 (98.4-100%), and influenza B (93.8-10%)
• Sp all high 99.7-100%
Slide 37JCM 2013;51(1):352-53
• Nanosphere Verigene RV+ test – random access kit that does not require pre-extraction;
detects influenza A/B (2009 H1N1, H1 and H3) RSV A/B• Focus Diagnostics Simplexa kit
– Kit assessed requires pre-extraction and batched testing but direct kit which does not require pre-extraction is available; detect influenza A/B, RSV A/B
Slide 38
Results
• Tested NP swabs prospectively and retrospectively using Cepheid, Luminex, and RT-PCR LDTs as reference
• Sn/Sp (%) Nanosphere Simplexa– Influenza A 96.6/100 82.8/99.7– Influenza B 100/99.7 76.2/100– RSV 100/100 94.6/100
JCM 2013;51(1):352-53
Slide 39
Random Access Automated PCR Platforms
• Xpert (Cepheid)• Verigene (Nanosphere)• Simplexa Direct Testing (Focus Diagnostics)• BDMax (BD)• Liat (IQuum)
Slide 40
Automation
• Time efficient• Personnel efficient
Slide 41WASP, Copan Diagnostics
Slide 42Inoqula, Kiestra
Slide 43Previ-Isola, Biomérieux
Slide 44Innova, BD
Slide 45
• Compared Previ Isola polyurethane swabs to standard swabs on 112 paired samples
• Noted 2.6 hours labour savings • Noted 71% concordance with culture and 55%
concordance with gram smear; where discordant, predominantly higher CFU and better gram stain characteristics with Previ Isola
JCM 2012;50(8):2732-36
Slide 46JCM published online ahead of print on March 20 2013
• Summary overview of automation • Overview of currently available automated
specimen processors
Slide 47Clin Microbiol Infect 2011;17:655-60
• Another useful summary overview of automation
• Overview of currently available automated specimen processors
Slide 48
Fecal Transplant
• If your microbiology laboratory has not yet been asked to process fecal transplants, it may soon
Slide 49NEJM 2013 (published online January 16, 2013)
Slide 50
Results• RCT for patients with recurrent C. difficile• assessed fecal transplant by NG tube after
vancomycin vs vancomycin alone or vancomycin bowel prep
• Cures:– 81% of fecal transplants were cured (94% if a
second donor was found)– 31% vancomycin for 2 weeks– 23% vancomycin with bowel lavage
NEJM 2013 (published online January 16, 2013)
Slide 51
What Does this Mean to You?
• Donor screening• Good manufacturing procedures
– microbiology or pharmacy?• Advice regarding optimal administration
– Work with infectious disease colleagues/gastroenterologists
• Still a lot of unknowns
NEJM 2013 (published online January 16, 2013)
Slide 52
• Guidance documentation regarding donor selection, screening tests, transplant preparation
• Caveat – mostly expert opinion
Clin Gastro and Hep 2011;9(12):1044-9
Slide 53
What’s Hot -Take Home Messages
• MALDI-TOF– Low cost, low tech time, accurate identification– If you have not already considered MALDI-TOF, it is
time to do so• Next Generation Sequencing
– Better resolution at differentiating relatedness– Be on the lookout for novel diagnostics instruments
using next generation sequence technologies– Expect possible requests next generation
sequencing in specific outbreak situations
Slide 54
• Random Access Automated PCR– Random access, fast TAT, low tech time– Evaluate your needs and consider moving to random
access PCR when results are needed in a timely fashion (TB, influenza, C. difficile, ARO screening)
• Automation– Labour savings, better quality smears/plates– If you haven’t considered this, it’s time to do so
• Fecal Transplants? – be prepared to be asked!– Be prepared to answer!
What’s Hot -Take Home Messages
Slide 55
Questions?